Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6476905 | 0.84 | TSHR (0.62) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL11135147 | 0.84 | ALDH1A1 (0.77) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL11139506 | 0.84 | ALDH1A1 (0.77) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| Benzene SCHEMBL7861838 | 0.83 | MAPK1 (0.75) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL2008321 | 0.83 | MAPK1 (0.75) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL11137490 | 0.83 | ALDH1A1 (0.75) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL11135285 | 0.83 | ALDH1A1 (0.75) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL7017531 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL7017529 | 0.82 | ALDH1A1 (0.59) | ALDH1A1MAPK1TSHRLMNANPSR1 | |
| SCHEMBL5547223 | 0.77 | ALDH1A1 (0.69) | ALDH1A1MAPK1TSHRLMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1252150-B1 | HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | claimed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | ALDH1A1 687/4885MAPK1 2074/4885TSHR 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.